19 February 2015 - Deborah Wilkes
Archived
Actavis said it would continue to invest in its OTC business, as the company announced plans to change its corporate name to Allergan after it completes the US$66 billion acquisition of the Botox maker.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.